Latest Breaking News On - Impax laboratories inc - Page 9 : comparemela.com

To embed, copy and paste the code into your website or blog: On April 13, 2021, the U.S. Court of Appeals for the Fifth Circuit issued an opinion in  Impax Laboratories, Inc v. Federal Trade Commission, affirming the Federal Trade Commission s (FTC) unanimous decision that Endo Pharmaceuticals, Inc. s settlement with Impax Laboratories, Inc. constituted a reverse payment and violated Section 5 of the FTC Act. In so doing, the Fifth Circuit reiterated the rule-of-reason burden-shifting framework for reverse payment cases, and also granted considerable deference to the FTC. Background and Procedural History In the underlying patent litigation, Endo Pharmaceuticals, Inc. (Endo) sued first-filer Impax Laboratories, Inc. (Impax) in 2008. At that time, Endo planned to introduce a new crush-resistant formulation of Opana ER (extended-release oxymorphone) and allegedly wanted to delay Impax s generic entry until after the new formulation launched. In June 2010, right before the patent

United statesWilson sonsini goodrich rosatiEndo pharmsTeikoku pharmaJustice robertsEndo pharmaceuticals incActavis incUs courtDrug administrationGilead sci incImpax laboratories incAmneal pharmaceuticals incUs supreme courtImpax laboratoriesWilson sonsini goodrichFifth circuit